10-Q: Eli Lilly Soars on Blockbuster Drug Sales Growth

Eli Lilly reports exceptional Q2 and H1 2025 financial results, driven by surging demand for Mounjaro and Zepbound, alongside significant pipeline advancements.

Summary

• Revenue for the three months ended June 30, 2025, increased by 38% to $15.56 billion, up from $11.30 billion in the prior year period.
• Revenue for the six months ended June 30, 2025, increased by 41% to $28.29 billion, up from $20.07 billion in the prior year period.
• Net income for the three months ended June 30, 2025, rose 91% to $5.66 billion, compared to $2.97 billion in the same period last year.
• Net income for the six months ended June 30, 2025, increased 62% to $8.42 billion, up from $5.21 billion in the prior year period.
• Diluted earnings per share (EPS) for the three months ended June 30, 2025, were $6.29, a 92% increase from $3.28.
• Diluted EPS for the six months ended June 30, 2025, were $9.35, a 62% increase from $5.76.
• Gross margin as a percentage of revenue improved to 84.3% for the three months and 83.5% for the six months ended June 30, 2025, primarily due to improved cost of production and favorable product mix.
• Mounjaro revenue increased 68% to $5.20 billion for the three months and 85% to $9.04 billion for the six months ended June 30, 2025, reflecting strong demand.
• Zepbound revenue in the U.S. was $3.38 billion for the three months and $5.69 billion for the six months ended June 30, 2025, driven by increased demand.
• Research and development expenses increased 23% to $3.34 billion for the three months and 16% to $6.07 billion for the six months ended June 30, 2025, due to continued investments in the portfolio.
• Marketing, selling, and administrative expenses increased 30% to $2.75 billion for the three months and 28% to $5.22 billion for the six months ended June 30, 2025, driven by promotional efforts.
• Acquired in-process research and development (IPR&D) charges for the six months ended June 30, 2025, were $1.73 billion, primarily related to the acquisition of Scorpion Therapeutics' PI3K inhibitor program STX-478.
• The effective tax rate for the six months ended June 30, 2025, was 17.7%, up from 13.9% in the prior year, due to the unfavorable tax impact of a non-deductible acquired IPR&D charge.

Sentiment

Score: 9

Explanation: The company demonstrates exceptional financial performance with robust revenue, net income, and EPS growth driven by strong demand for key products. Significant pipeline advancements and strategic acquisitions further bolster future prospects. While increased expenses and ongoing litigation present challenges, the overall outlook is highly positive.

Positives

• Achieved substantial revenue growth of 38% for the quarter and 41% for the six-month period, demonstrating strong market penetration and demand.
• Net income and diluted EPS more than doubled for the quarter and increased significantly for the six-month period, indicating strong profitability.
• Gross margin percentage improved, reflecting efficient production costs and a favorable product mix.
• Mounjaro and Zepbound continue to drive exceptional volume growth, particularly in the U.S. and new international markets.
• Significant advancements in the clinical pipeline, including positive Phase 3 trial results for tirzepatide (cardiovascular outcomes) and orforglipron (obesity and type 2 diabetes).
• Regulatory approvals received for Mirikizumab in Japan for Crohn's disease and Pirtobrutinib in Europe for chronic lymphocytic leukemia.
• Positive opinion from EMA CHMP for Donanemab for early symptomatic Alzheimer's disease, signaling potential future approval.
• Strategic acquisitions of Verve Therapeutics and SiteOne Therapeutics in July 2025 are expected to enhance the pipeline in cardiovascular disease and pain management.
• The company maintains strong liquidity with sufficient cash and cash equivalents, and access to credit facilities to fund capital requirements.

Negatives

• Lower realized prices partially offset volume increases for Mounjaro and Zepbound in the U.S.
• Increased research and development expenses reflect higher investments in the portfolio, impacting short-term profitability.
• Marketing, selling, and administrative expenses rose significantly due to promotional efforts for new and ongoing product launches.
• A substantial acquired IPR&D charge of $1.73 billion for the six months ended June 30, 2025, impacted net income.
• The effective tax rate increased to 17.7% for the six months ended June 30, 2025, partly due to the non-deductible acquired IPR&D charge.
• Ongoing litigation related to Emgality patents, Brazil labor claims, 340B program, insulin pricing, and Actos, which could result in adverse outcomes.
• The U.S. application for tirzepatide for heart failure with preserved ejection fraction was withdrawn.

Risks

• Significant costs and uncertainties associated with pharmaceutical research and development, including regulatory approval timing.
• Uncertain outcomes and related costs of acquisitions and business development transactions.
• Intense competition affecting products, pipeline, and the industry.
• Continued pricing pressures and actions by governmental and private entities impacting pricing, reimbursement, and patient access.
• Safety or efficacy concerns related to company or competitive products.
• Dependence on a relatively small number of products or product classes for a significant portion of total revenue and a consolidated supply chain.
• Expiration of intellectual property protection for products and competition from generic and biosimilar products.
• Challenges in protecting and enforcing patents and other intellectual property, and changes in patent law.
• Information technology system inadequacies, security breaches, or operating failures.
• Unauthorized access, disclosure, or compromise of confidential information and violations of data protection laws.
• Product supply and regulatory approval issues due to manufacturing difficulties, disruptions, or shortages, including from unpredictable demand, labor shortages, or cyber-attacks.
• Reliance on third-party relationships and outsourcing arrangements.
• Potential exacerbation of competitive, regulatory, litigation, and cybersecurity risks due to the use of artificial intelligence.
• Impact of global macroeconomic conditions, including uneven economic growth, trade disputes, and international conflicts.
• Fluctuations in foreign currency exchange rates, changes in interest rates, and inflation.
• Significant and sudden declines or volatility in the trading price of common stock.
• Litigation, investigations, or other proceedings involving past, current, or future products or activities.
• Changes in tax law and regulation, tax rates, or events differing from tax position assumptions.
• Regulatory changes and developments, including increased scrutiny and potential actions regarding operations and products.
• Risks from the proliferation of counterfeit, misbranded, adulterated, or illegally compounded products, particularly incretins.
• Actual or perceived deviation from environmental-, social-, or governance-related requirements or expectations.
• Asset impairments and restructuring charges.
• Changes in accounting and reporting standards.
• Demand for incretin medicines exceeding production capacity, leading to periodic unavailability of certain presentations and dose levels.
• Continued regulatory focus on business combinations in the industry, potentially delaying or increasing costs of business development activities.

Future Outlook

The company expects the newly enacted One Big Beautiful Bill Act (OBBBA) to increase its effective income tax rate to approximately 19% for the year ending December 31, 2025, while decreasing income tax payments during the second half of 2025. Continued investments in global manufacturing facilities are anticipated to result in meaningfully higher capital expenditures over the next several years. The company also expects additional significant products to be selected for government-set prices under the Inflation Reduction Act in future years, similar to Jardiance.

Management Comments

• Our long-term success depends on our ability to continually discover or acquire, develop, and commercialize innovative new medicines.
• We view our business development activity as a way to enhance or refine our pipeline and strengthen our business.
• While we seek to manage a portion of these exposures through hedging and other risk management techniques, significant fluctuations in currency rates can have a material impact, either positive or negative, on our consolidated results of operations in any given period.
• We believe our available cash and cash equivalents, together with our ability to generate operating cash flow and our access to short-term and long-term borrowings, are sufficient to fund our existing and planned capital requirements.
• Lilly will continue to consider all options, including filing lawsuits where appropriate, to address unlawful practices and the patient safety risks of unapproved, untested, and manipulated drugs.

Industry Context

The pharmaceutical industry continues to face global pressure on drug pricing, reimbursement, and access, driven by governmental and private cost containment efforts, including mandated discounts and price reporting. The Inflation Reduction Act of 2022 (IRA) is significantly influencing business strategies, with key products like Jardiance already selected for government-set prices. The proliferation of counterfeit and compounded incretins poses a patient safety risk and challenges regulatory drug approval processes. Despite these headwinds, the demand for innovative medicines, particularly in cardiometabolic health, oncology, and immunology, remains strong, driving significant R&D investment and strategic acquisitions across the sector.

Comparison to Industry Standards

• NA

Legal Proceedings

• Emgality Patent Litigation: Teva's appeal is pending at the U.S. Court of Appeals for the Federal Circuit after the trial court ruled in the company's favor, finding Teva's asserted claims invalid.
• Brazil Litigation Cosmopolis Facility Labor Attorney Litigation: The appeals court generally affirmed a trial court ruling against Lilly Brasil, which included a liquidated award of approximately $273 million (1.49 billion Brazilian reais). Appeals to the superior labor court (TST) are pending, and a property freeze of approximately $28 million (154 million Brazilian reais) is in place.
• 340B Litigation and Investigations: A lawsuit challenging HHS's 340B program interpretations is pending appeal at the U.S. Court of Appeals for the Seventh Circuit. Administrative dispute resolution (ADR) petitions are held in abeyance. A putative class action lawsuit alleging antitrust and unjust enrichment claims related to 340B programs was dismissed but later reversed and remanded by the U.S. Court of Appeals for the Second Circuit. Various civil investigative subpoenas and information requests from state attorneys general are ongoing.
• Insulin Pricing Litigation: Multiple lawsuits, including putative class actions, are coordinated in a federal multidistrict litigation (MDL). A proposed settlement with a consumer class was terminated after class certification was denied. Non-monetary settlements were reached with the Minnesota and New York attorneys general. A Michigan attorney general lawsuit, previously dismissed, has been granted leave to appeal by the Michigan Supreme Court.
• Average Manufacturer Price Litigation: A jury returned a verdict in favor of the relator, and the company has appealed to the U.S. Court of Appeals for the Seventh Circuit.
• Actos Litigation: A third-party payer class action is ongoing in the U.S. District Court for the Central District of California. Class certification was granted, and the Ninth Circuit denied the company's appeal, with a petition for rehearing en banc filed.
• Mounjaro, Trulicity, and Zepbound Product Liability Litigation: Various lawsuits alleging injuries from incretin medicines are coordinated in a federal MDL in Pennsylvania, with additional cases in state courts and two class action petitions in Israel.
• Branchburg Manufacturing Facility: The company is cooperating with a U.S. Department of Justice subpoena requesting documents related to its manufacturing site in Branchburg, New Jersey.
• Puerto Rico Tax Matter: A lawsuit filed by the Municipality of Carolina was dismissed with prejudice after an out-of-court settlement.
• Research Corporation Technologies, Inc.: A confidential agreement was reached in a lawsuit asserting damages claims related to manufacturing processes, with the company's appeal pending at the U.S. Court of Appeals for the Ninth Circuit.

Stakeholder Impact

• Shareholders: Significant increases in revenue, net income, and EPS are highly positive, indicating strong financial performance and potential for increased shareholder value. The ongoing share repurchase program and dividend payments further benefit shareholders.
• Patients: Continued investment in R&D and successful clinical trial outcomes for new medicines (e.g., tirzepatide, orforglipron, donanemab) promise improved treatment options for various diseases. However, supply constraints for incretin medicines may impact patient access.
• Employees: The acquisition of a manufacturing facility in Wisconsin and ongoing expansion of manufacturing capacity suggest job stability and potential growth opportunities. The goodwill recognized from the Wisconsin acquisition is partly attributed to the assembled workforce.
• Customers (Wholesale Distributors, Healthcare Providers): Strong demand for key products benefits distributors. However, lower realized prices for some products and ongoing pricing pressures from governmental and private payers could impact profitability for certain customers.
• Suppliers: Increased manufacturing capacity and demand for materials will likely lead to continued or increased business for suppliers, though the company has agreements that could require payments if specified amounts of goods or services are not purchased.
• Creditors: The issuance of $6.50 billion in fixed-rate notes increases total debt, but strong operating cash flows and available credit facilities suggest continued ability to meet financial obligations.

Next Steps

• Continue evaluating the impact of the newly enacted One Big Beautiful Bill Act (OBBBA) on effective income tax rate and payments for the year ending December 31, 2025.
• Proceed with ongoing production increases and delivery presentation initiatives for incretin medicines, with additional manufacturing capacity expected to be operational over the next several years.
• Monitor and respond to potential selection of additional significant products for government-set prices under the Inflation Reduction Act in future years.
• Continue to vigorously prosecute or defend positions in ongoing legal proceedings, including patent litigation, Brazil labor claims, 340B program disputes, insulin pricing litigation, and product liability lawsuits.
• Integrate newly acquired assets from Verve Therapeutics and SiteOne Therapeutics into operations and advance their respective pipelines.
• Continue to invest in early and late-stage research and development to enhance the product portfolio.

Key Dates

Recommendation

Eli Lilly's Q2 and H1 2025 results demonstrate exceptional growth, driven by the blockbuster performance of Mounjaro and Zepbound, which are addressing significant unmet medical needs in diabetes and obesity. The substantial increases in revenue, net income, and EPS, coupled with improved gross margins, highlight robust operational efficiency and market leadership. The company's deep and advancing pipeline, with multiple positive Phase 3 readouts and strategic acquisitions, provides a strong foundation for sustained future growth. While increased R&D and marketing expenses are noted, these are necessary investments for long-term value creation. The ongoing litigation and regulatory pressures are inherent to the pharmaceutical industry, and the company appears to be managing these risks. The overall financial health, market position, and future prospects make Eli Lilly a compelling 'strong buy' for investors seeking growth in the pharmaceutical sector.

Keywords

Pharmaceuticals, Biotechnology, Drug Development, Cardiometabolic Health, Oncology, Immunology, Neuroscience, Mounjaro, Zepbound, Verzenio, Tirzepatide, Orforglipron, GLP-1, Diabetes, Obesity, Cancer, Autoimmune Diseases, Alzheimer's Disease, SEC Filing, Earnings Report, Q2 2025, Financial Results